These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 29356433

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Investigation on acute effects of enzyme replacement therapy and influence of clinical severity on physiological variables related to exercise tolerance in patients with late onset Pompe disease.
    Sechi A, Salvadego D, Da Ponte A, Bertin N, Dardis A, Cattarossi S, Devigili G, Reccardini F, Bembi B, Grassi B.
    Neuromuscul Disord; 2017 Jun; 27(6):542-549. PubMed ID: 28433478
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI, Samjoo IA, Hettinga BP, Koeberl DD, Zhang H, Hawke TJ, Nissar AA, Ali T, Brandt L, Ansari MU, Hazari H, Patel N, Amon J, Tarnopolsky MA.
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE, Bjartmar C, Morgan C, Casey R, Charrow J, Clancy JP, Dasouki M, DeArmey S, Nedd K, Nevins M, Peters H, Phillips D, Spigelman Z, Tifft C, Kishnani PS.
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [Abstract] [Full Text] [Related]

  • 9. Individualized Assessment of Exercise Capacity in Response to Acute and Long-Term Enzyme Replacement Therapy in Pediatric Pompe Disease.
    Bar-Yoseph R, Tal G, Dumin E, Hanna M, Mainzer G, Zucker-Toledano M, Shallufi G, Jahshan M, Mandel H, Bentur L.
    J Pers Med; 2021 Oct 28; 11(11):. PubMed ID: 34834457
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M, Violano R, Ronchi D, Mondello S, Nascimbeni A, Colombo I, Fagiolari G, Bordoni A, Fortunato F, Lucchini V, Saredi S, Filosto M, Musumeci O, Tonin P, Mongini T, Previtali S, Morandi L, Angelini C, Mora M, Sandri M, Sciacco M, Toscano A, Comi GP, Moggio M.
    Neuropathol Appl Neurobiol; 2018 Aug 28; 44(5):449-462. PubMed ID: 28574618
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE, Beckemeyer AA, Kishnani PS.
    Am J Med Genet C Semin Med Genet; 2012 Feb 15; 160C(1):69-79. PubMed ID: 22252989
    [Abstract] [Full Text] [Related]

  • 15. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
    Sarah B, Giovanna B, Emanuela K, Nadi N, Josè V, Alberto P.
    J Neurol; 2022 Feb 15; 269(2):733-741. PubMed ID: 33851281
    [Abstract] [Full Text] [Related]

  • 16. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM, Huidekoper HH, Kruijshaar ME, Rizopoulos D, Hahn A, Mongini TE, Labarthe F, Tardieu M, Chabrol B, Brassier A, Parini R, Parenti G, van der Beek NAME, van der Ploeg AT, van den Hout JMP, European Pompe Consortium project group on classic infantile Pompe disease.
    Lancet Child Adolesc Health; 2022 Jan 15; 6(1):28-37. PubMed ID: 34822769
    [Abstract] [Full Text] [Related]

  • 17. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G, Krase A, Papadimas G, Papadopoulos C, Kavouras SA, Manta P.
    Mol Genet Metab; 2012 Dec 15; 107(4):669-73. PubMed ID: 23146291
    [Abstract] [Full Text] [Related]

  • 18. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.
    Hundsberger T, Rösler KM, Findling O.
    J Neurol; 2014 Sep 15; 261(9):1684-90. PubMed ID: 24923245
    [Abstract] [Full Text] [Related]

  • 19. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO, Pope R, Li S, Kishnani PS, Steet R, Koeberl DD.
    Mol Genet Metab; 2016 Feb 15; 117(2):114-9. PubMed ID: 26454691
    [Abstract] [Full Text] [Related]

  • 20. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up.
    Andreassen CS, Schlütter JM, Vissing J, Andersen H.
    Mol Genet Metab; 2014 May 15; 112(1):40-3. PubMed ID: 24685124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.